Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5879566 | 0.75 | ITGB3 (0.54) | POLB | |
| SCHEMBL8377645 | 0.74 | EGFR (0.40) | NR1H2NR1H3EGFRKDM4EKMT2A | |
| SCHEMBL1675990 | 0.74 | EGFR (0.56) | EGFRPOLBKMT2ACYP1A2 | |
| SCHEMBL3223094 | 0.73 | ITGB3 (0.42) | — | |
| SCHEMBL5879694 | 0.73 | EGFR (0.41) | EGFRPOLBALDH1A1 | |
| SCHEMBL1388649 | 0.70 | EGFR (0.60) | EGFRALDH1A1KMT2AMEN1 | |
| SCHEMBL8379506 | 0.70 | ADRA2A (0.38) | EGFRPOLBALDH1A1 | |
| SCHEMBL13493012 | 0.69 | ALDH1A1 (0.43) | NR1H2NR1H3KDM4EALDH1A1KMT2A | |
| SCHEMBL8174003 | 0.68 | ALDH1A1 (0.47) | EGFRKDM4EPOLBTDP1ALDH1A1 | |
| SCHEMBL3227107 | 0.68 | NR1H2 (0.52) | NR1H2NR1H3DRD2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | GENESTE HERVE | 2010-02-25 | — | — | US | disclosed |
| US-20040077638-A1 | Novel integrin receptor antagonists | BASF AKTIENGESELLCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | ITGB3, ITGAL, ITGB4 | NR1H2 1943/4885NR1H3 1578/4885EGFR 256/4885 |
| US-20040077638-A1 | Novel integrin receptor antagonists | ITGB3, ITGAV, ITGA2B | NR1H2 2320/4885NR1H3 2173/4885EGFR 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.